Most recently, it's been determined that conolidine and the above derivatives act to the atypical chemokine receptor 3 (ACKR3. Expressed in identical spots as classical opioid receptors, it binds to the big selection of endogenous opioids. Unlike most opioid receptors, this receptor functions like a scavenger and doesn't activate a second messenger